Lung cancer therapy using an engineered respiratory syncytial virus
AssigneeCz Biomed Corp.
InventorsWeidong Zhang, Lixian Jiang, Calvin Cao
Life of this patent
Estimating the term…
Abstract
The invention discloses an engineered oncolytic respiratory syncytial virus (RSV), NS1 gene deficient RSV, and its usage to treat lung cancer by killing cancer cells with in vitro and in vivo evidences.
Claims9
A method of treating a neoplasm in a subject, comprising administering to the subject an oncolytically effective amount of a respiratory syncytial virus (RSV) with the NS1 gene deleted or mutated so that it is no longer functional, thereby treating the neoplasm in the subject.
A method of treating lung cancer comprising resuspending an oncolytic respiratory syncytial virus (RSV) with the NS1 gene deleted or mutated so that it is no longer functional in saline or medium, and injecting the RSV suspension into cancerous tissue or intravenously.
Dependencies are inferred from the claim text.